Treatment of early stage non-small cell lung cancer: Surgery or stereotactic ablative radiotherapy?

PDF

___

1.National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395- 409. [CrossRef]
2.Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of ma- lignant tumours. J Thorac Oncol 2007;2:706-14. [CrossRef]
3.Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K; American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:234S- 42S.
4.Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT; American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132:161S-77S.
5.Puri V, Meyers BF. Optimal initial pathologic mediastinal stag- ing of lung cancer: EUS, EBUS, mediastinoscopy. In: Ferguson MK, ed. Difficult decisions in thoracic surgery. London: Spring- er; 2011. p. 67-75. [CrossRef]
6.Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA; American College of Chest Physicians. Invasive mediastinal staging of lung cancer: ACCP evidence- based clinical prac- tice guidelines (2nd edition). Chest 2007;132:202S-20S.
7. Boffa DJ, Kosinski AS, Paul S, Mitchell JD, Onaitis M. Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg 2012;94:347-53. [CrossRef]
8. Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, Onaitis MW, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg 2010;139:366-78. [CrossRef]
9. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80:2051-6. [CrossRef]
10. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, 2nd, Landreneau RJ, et al. Morbidity and mortality of major pulmo- nary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006;81:1013-9. [CrossRef]
11. Donington J, Ferguson M, Mazzone P, Handy J, Jr, Schuchert M, Fernando H, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for eval- uation and management for high-risk patients with stage I non- small cell lung cancer. Chest 2012;142:1620-35. [CrossRef]
12. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser re- section. J Thorac Cardiovasc Surg 2005;129:87-93. [CrossRef]
13. Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than lim- ited pulmonary resection for T1N0M0 non-small cell lung cancer pa- tients? Interact Cardiovasc Thorac Surg 2009;8:364-72. [CrossRef]
14. Ceppa DP, Kosinski AS, Berry MF, Tong BC, Harpole DH, Mitch- ell JD, et al. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Sur- geons Database analysis. Ann Surg 2012;256:487-93. [CrossRef]
15. Gopaldas RR, Bakaeen FG, Dao TK, Walsh GL, Swisher SG, Chu D. Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619 patients. Ann Thorac Surg 2010;89:1563-70. [CrossRef]
16. Darling GE, Allen MS, Decker PA, Ballman K, Maltha- ner RA, Inculet RI, et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, pro- spective American College of Surgeons Oncology Group Z0030 trial. Chest 2011;139:1124-9. [CrossRef]
17. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tu- mors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-39. [CrossRef]
18. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early- stage lung cancer. J Thorac Oncol 2011;6:2036-43. [CrossRef]
19. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to sur- gery? Int J Radiat Oncol Biol Phys 2011;81:1352-8. [CrossRef]
20. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, et al. Outcomes of stereotactic ablative radiothera- py in patients with potentially operable stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2011;83:348-53. [CrossRef]
21. Neri S, Takahashi Y, Terashi T, Hamakawa H, Tomii K, Kataka- mi N, et al. Surgical treatment of local recurrence after stereo- tactic body radiotherapy for primary and metastatic lung can- cers. J Thorac Oncol 2010;5:2003-7. [CrossRef]
22. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radi- ation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2010;140:377-86. [CrossRef]
23. Kothary N, Heit JJ, Louie JD, Kuo WT, Loo BW, Jr, Koong A, et al. Safety and efficacy of percutaneous fiducial marker implan- tation for image-guided radiation therapy. J Vasc Interv Radiol 2009;20:235-9. [CrossRef]
24. Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sornsen de Koste JR, Senan S. Four- dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 2004;60:1283-90. [CrossRef]
25. Kimura T, Hirokawa Y, Murakami Y, Tsujimura M, Nakashima T, Ohno Y, et al. Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radio- therapy. Int J Radiat Oncol Biol Phys 2004;60:1307-13. [CrossRef]
26. Guckenberger M, Krieger T, Richter A, Baier K, Wilbert J, Swee- ney RA, et al. Potential of image- guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body ra- diother- apy. Radiother Oncol 2009;91:288-95. [CrossRef]
27. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy in treatment of stage I non- small cell lung cancer. Lung Cancer 2003;41:1-11. [CrossRef]
28. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non- small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005;63:1010-5. [CrossRef]
29. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82. [CrossRef]
30. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated ster- eotactic radiothera- py for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70: 685-92. [CrossRef]
31. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoper- able stage I non- small-cell lung cancer patients treated with stereo- tactic body radiotherapy. J Clin Oncol 2009;27:3290-6. [CrossRef]
32. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-31. [CrossRef]
33. Hara R, Itami J, Kondo T, Aruga T, Uno T, Sasano N, et al. Clini- cal outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer 2006;106:1347-52. [CrossRef]
34. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, et al. Promising clini- cal outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Ra- diat Oncol Biol Phys 2006;66:117-25. [CrossRef]
35. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radio- therapy for early stage non-small- cell lung cancer: a retrospec- tive analysis. Lancet Oncol 2012;13:802-9. [CrossRef]
36. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012;84:1060-70. [CrossRef]
37. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a popu- lation-based time-trend analysis. J Clin Oncol 2010;28:5153-9. [CrossRef]
38. Noordijk EM, vd Poest Clement E, Hermans J, Wever AMJ, Leer JWH. Radiotherapy as an alternative to surgery in elderly pa- tientswith resectable lung cancer. Radiother Oncol 1988; 13:83-9. [CrossRef]
39. Sibley GS. Radiotherapy for patients with medically inopera- blestage I nonsmall cell lung carcinoma: smaller volumes and higherdoses-a review. Cancer 1998;82:433-8. [CrossRef]
40. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoper- able early stage lung cancer. JAMA 2010;303:1070-6. [CrossRef]
41. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-S100. [CrossRef]
42. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:847-52. [CrossRef]
43. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in ste- reotacticirradiation of lung tumors. Radiother Oncol 2005; 77:83-7. [CrossRef]
44. Loo BW Jr, Chang JY, Dawson LA, Kavanagh BD, Koong AC, Senan S. Stereotactic ablative radiotherapy: whats in a name ? Pract Radiat Oncol 2011;1:38-9. [CrossRef]
45. Reed CE, Harpole DH, Posther KE, et al. Z0050 trial: The util- ity of positron emission tomography in staging potentially op- erable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943-51. [CrossRef]
46. Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, et al. Matched-Pair and Propensity Score Compari- sons of Outcomes of Patients With Clinical Stage I Non-Small Cell Lung Cancer Treated With Resection or Stereotactic Radio- surgery. Cancer 2013;119:2683-91. [CrossRef]
47. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S. Curative treatment of stage I non-small-cell lung acancer in patients with severe COPD: stereotactic radiotherapy out- comes and systematic review. Int J Radiat Oncol Biol Phys 2012;82:1149-56. [CrossRef]
48. van der Voort van Zyp NC, Prevost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, et al. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010;77:31-7. [CrossRef]
49. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010;28:928-35. [CrossRef]
50. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, et al. Recommendations for implement- ing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009;4:1. [CrossRef]
51. Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJ, Slot- man BJ, Senan S. Patient-reported quality of life after stereotac- tic ablative radiotherapy for early- stage lung cancer. J Thorac Oncol 2012;7:1148-54. [CrossRef]
52. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012;82:457-62. [CrossRef]
53. Hoppe BS, LaserB, KowalskiAV, FontenlaSC, Pena- Greenberg E, Yorke ED, et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: whos atrisk? Int J Radiat Oncol Biol Phys 2008;72:1283-6. [CrossRef]
54. Corradetti MN, Haas AR, Rengan R. Central-airway necro- sis after stereotactic body-radiation therapy. N Engl J Med 2012;366:2327-9. [CrossRef]
55. G.M Videtic, C.Hu, A.Singh et al. Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase 2 Study Com- paring 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2013;87(Suppl 2): 3. [CrossRef]
56. Widder J, Postmus D, Ubbels JF, Wiegman EM, Langendijk JA. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys 2011;81:e291-7. [CrossRef]
57. Hamamoto Y, Kataoka M, Yamashita M, Nogami N, Sugawara Y, Kozuki T, et al. Factors affecting the local control of stereo- tactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors. Jpn J Radiol 2012;30:430-4. [CrossRef]
58. Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Manabe Y, Nagai A, et al. Stereotactic body radiotherapy using a radiobi- ology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer 2012;118:2078-84. [CrossRef]
59. Timmerman RD, Paulus R, Pass HI, Gore E, Edelman MJ, Gal- vin MJ, et al. RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. J Clin Oncol 2013;31 (suppl; 7523).
60. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, et al. Clinical outcome and predictors of survival and pneumonitis af- ter stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 2012:10;7:152.